In silico design of recombinant multi-epitope vaccine against influenza A virus

Abstract

Background Influenza A virus is one of the leading causes of annual mortality. The emerging of novel escape variants of the influenza A virus is still a considerable challenge in the annual process of vaccine production. The evolution of vaccines ranks among the most critical successes in medicine and has eradicated numerous infectious diseases. Recently, multi-epitope vaccines, which are based on the selection of epitopes, have been increasingly investigated. Results This study utilized an immunoinformatic approach to design a recombinant multi-epitope vaccine based on a highly conserved epitope of hemagglutinin, neuraminidase, and membrane matrix proteins with fewer changes or mutate over time. The potential B cells, cytotoxic T lymphocytes (CTL), and CD4 T cell epitopes were identified. The recombinant multi-epitope vaccine was designed using specific linkers and a proper adjuvant. Moreover, some bioinformatics online servers and datasets were used to evaluate the immunogenicity and chemical properties of selected epitopes. In addition, Universal Immune System Simulator (UISS) in silico trial computational framework was run after influenza exposure and recombinant multi-epitope vaccine administration, showing a good immune response in terms of immunoglobulins of class G (IgG), T Helper 1 cells (TH1), epithelial cells (EP) and interferon gamma (IFN-g) levels. Furthermore, after a reverse translation (i.e., convertion of amino acid sequence to nucleotide one) and codon optimization phase, the optimized sequence was placed between the two EcoRV/MscI restriction sites in the PET32a+ vector. Conclusions The proposed “Recombinant multi-epitope vaccine” was predicted with unique and acceptable immunological properties. This recombinant multi-epitope vaccine can be successfully expressed in the prokaryotic system and accepted for immunogenicity studies against the influenza virus at the in silico level. The multi-epitope vaccine was then tested with the Universal Immune System Simulator (UISS) in silico trial platform. It revealed slight immune protection against the influenza virus, shedding the light that a multistep bioinformatics approach including molecular and cellular level is mandatory to avoid inappropriate vaccine efficacy predictions.

In silico design and immunoinformatics analysis of a universal multi-epitope vaccine against monkeypox virus

“…As a result, CTxB has been widely employed as an adjuvant in vaccine design to boost immune responses [ 108 – 110 ]. In this study, like many other studies, the AAY linker was used to connect CTL epitopes [ 85 , 111 , 112 ], the GGGGS linker to connect HTL epitopes [ 113 , 114 ], the KK linker to connect LBL epitopes [ 115 – 117 ], and the EAAAK linker to connect adjuvant [ 116 , 118 , 119 ]. The AAY linkers help to increase epitope presentation while decreasing the formation of junctional epitopes [ 120 ].…”

Toward a SARS-CoV-2 VLP Vaccine: HBc/G as a Carrier for SARS-CoV-2 Spike RBM and Nucleocapsid Protein-Derived Peptides

“…String of CTL epitopes was inserted along with an AAY linker between five individual CTL epitopes. It was predicted that the AAY linkers could significantly improve the expression of certain target proteins and enhance the immunogenicity of a multi-epitope influenza vaccine designed in silico for the production in E. coli [ 53 ]. However, the sequence to be inserted may affect the solubility and VLP-forming ability of chimeric HBc VLPs [ 54 ].…”

Moving forward through the in silico modeling of multiple sclerosis: Treatment layer implementation and validation

“…The simulator is built on a state-of-the-art agent-based model which describes the RRMS patient in terms of (i) a complete, multifunctional description of the immune system, (ii) a disease-specific RRMS extension, and (iii) an easily extensible treatment module. The multifunctional base model has been deployed to describe a variety of immune-related pathologies and vaccines [26] , [27] , [28] . The model includes a detailed description of both innate and adaptive immune system, such as different cell types, key immune system processes, cytokines and chemokines signaling.…”